Neurophet, a Korean AI-backed brain disease diagnosis and treatment developer, said Tuesday that it has signed a supply agreement with the National University of Singapore (NUS) and Singapore General Hospital (SGH) for its PET imaging analysis software, Neurophet SCALE PET.

Under the agreement, Neurophet will provide the software while also collaborating with the two institutions to validate its clinical utility using brain MRI and PET imaging data.

Neurophet believes that the partnership will accelerate the commercialization of its technology by demonstrating its effectiveness in real-world clinical environments.

Neurophet SCALE PET is designed to quantitatively analyze biomarkers captured by PET tracers through PET and MRI imaging.

The software automatically calculates standardized uptake value ratio (SUVR) values, which measure tracer uptake in different brain regions relative to a reference area with constant metabolic activity.

It can target a wide range of brain imaging biomarkers, including Alzheimer’s disease markers such as amyloid beta and tau proteins, as well as FDG (fluorodeoxyglucose) and dopamine.

Founded as Singapore’s first national university, NUS ranked eighth in the QS World University Rankings 2025 and operates a medical-focused campus.

SGH, meanwhile, was named Asia’s top hospital and ranked 11th globally in Newsweek’s 2024 World’s Best Hospitals list, underscoring its status as one of the region’s most advanced medical centers.

“With the supply of Neurophet SCALE PET to leading research institutions and hospitals in Singapore, we now have the opportunity to prove the reliability and clinical value of our technology,” Neurophet Co-CEO Jake Been said. “This milestone will also serve as a springboard for expanding our presence in Southeast Asia.”